Global HER2 testing survey raises questions about priorities for breast cancer resources

(European Society for Medical Oncology) A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries. The results were presented at the ESMO Breast Cancer Congress 2019, Berlin, May 2-4, 2019.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Condition:   Breast Cancer Intervention:   Diagnostic Test: SPECT Sponsors:   Tomsk National Research Medical Center of the Russian Academy of Sciences;   KTH Royal Institute of Technology;   Uppsala University Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Negative Breast Cancer Intervention:   Drug: Pembrolizumab Sponsors:   University of Malaya;   Merck Sharp & Dohme (MSD);   National University Hospital, Singapore;   Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: SIBP-01;   Drug: Herceptin;   Drug: Docetaxel;   Drug: Carboplatin Sponsors:   Shanghai Institute Of Biological Products;   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-Negative Breast Cancer Intervention:   Drug: Pembrolizumab Sponsors:   University of Malaya;   Merck Sharp & Dohme (MSD);   National University Hospital, Singapore;   Clinical Research Malaysia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HER2-positive Early Breast Cancer Interventions:   Drug: SIBP-01;   Drug: Herceptin;   Drug: Docetaxel;   Drug: Carboplatin Sponsors:   Shanghai Institute Of Biological Products;   Fudan University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Pembrolizumab;   Drug: Trastuzumab Biosimilar ABP 980;   Drug: Pertuzumab Sponsors:   West German Study Group;   Merck Sharp & Dohme Corp.;   Amgen;   NanoString Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Breast Cancer Interventions:   Drug: Pembrolizumab;   Drug: Trastuzumab Biosimilar ABP 980;   Drug: Pertuzumab Sponsors:   West German Study Group;   Merck Sharp & Dohme Corp.;   Amgen;   NanoString Technologies, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Metastatic Breast Cancer Interventions:   Drug: Abemaciclib;   Drug: Nonsteroidal Aromatase Inhibitor (NSAI) Sponsor:   Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Politics